BCG and Kawasaki disease in Mexico and Japan

Hum Vaccin Immunother. 2017 May 4;13(5):1091-1093. doi: 10.1080/21645515.2016.1267083. Epub 2017 Mar 10.


Dr. Tomisaku Kawasaki was the first to describe BCG reactivation in Kawasaki Disease (KD), and this sign is present in about 30-50% of KD patients. It is a very specific early sign of the disease and although it has been recognized for decades, its pathophysiology continues to be an enigma. Recently, Yamada et al. reported a severe BCG reaction with tuberculid in 2 Japanese KD patients. We present 2 cases with KD and severe BCG reaction, one from Japan and the other from Mexico and review the policies of administration of BCG in both countries. The BCG vaccine has a worldwide coverage of 88%. Differences in BCG strains and methods of administration may influence BCG reactions in KD. The BCG reaction in the inoculation site may represent the most useful sign in KD.

Keywords: BCG; Kawasaki disease; Tuberculid; tokyo172.

Publication types

  • Case Reports

MeSH terms

  • BCG Vaccine / adverse effects*
  • BCG Vaccine / immunology*
  • Cross Reactions
  • Female
  • Humans
  • Infant
  • Japan / epidemiology
  • Male
  • Mexico / epidemiology
  • Mucocutaneous Lymph Node Syndrome / immunology*
  • Mycobacterium bovis / immunology*
  • Tuberculosis, Cutaneous / etiology
  • Tuberculosis, Cutaneous / immunology*
  • Vaccination


  • BCG Vaccine